Updates on treatments for Pulmonary Fibrosis

In this webinar, Professor Dan Chambers provides an overview of the current treatment options for pulmonary fibrosis (PF), as well as an insight into the latest advancements and breakthroughs emerging from clinical trials, offering a glimpse into the promising future of PF treatments. We were also joined by two consumers living with PF, who shared their lived experience and practical tips for navigating day-to-day life on PF treatments.

Pulmonary fibrosis is increasingly recognised as a common, age-related lung disease. Advances in research have revealed that idiopathic pulmonary fibrosis (IPF) is often driven by accelerated lung aging, genetic mutations, and telomere shortening, which impair lung cell repair and promote scarring. New studies have identified harmful immune cells which can drive fibrosis. Targeting these pathways offers hope for future treatments. Early diagnosis is improving, and awareness is growing, enabling more effective use of current therapies like nintedanib and pirfenidone, and paving the way for next-generation therapies.

Clinical trials in Australia, supported by the Lung Foundation Australia and the Pulmonary Fibrosis Australasian Clinical Trials (PACT) Network, are testing innovative therapies—including mRNA-based telomere repair and compounds from native plants that deactivate scarring cells. These breakthroughs aim not just to slow fibrosis but to halt or reverse it.

Patients are encouraged to join clinical trials to access cutting-edge care and help shape the future of IPF treatment. Pulmonary fibrosis patients across Australia and New Zealand now have greater access to clinical trials through the PACT Network, offering hope through cutting-edge treatments. These trials target the root causes of fibrosis, including genetic mutations and pro-fibrotic immune cells. Patients emphasise the value of compassionate care, accurate information, and peer support. Programs led by specialists and supported by the Lung Foundation Australia empower patients to participate in research and manage their condition with confidence. The webinar highlights that with ongoing breakthroughs, the future of IPF treatment is brighter—offering not just hope, but real progress.